Sign In
Buy OPRX
$4.95
-0.330 (-6.25%)
At Close: Jun 03, 2026
OptimizeRx Sets Second Quarter Fiscal 2022 Conference Call for Tuesday, August 9 at 4:30 p.m. ET
07:30am, Thursday, 21'st Jul 2022
ROCHESTER, Mich., July 21, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on t
This Communication Services Stock Is Trading Higher By Over 82%, Here Are 45 Stocks Moving In Wednesday's Mid-Day Session
04:50pm, Wednesday, 20'th Jul 2022 Benzinga
Gainers
Direct Digital Holdings, Inc. (NASDAQ: DRCT) shares surged 82.2% to $2.6787. Direct Digital Holdings said its supply-side advertising platform, Colossus SSP, reported a 540% year-over-year gr
SVB Leerink Sees 'Cheaper Way' To Pharma Digital Marketing With This Stock
07:10pm, Friday, 15'th Jul 2022 Benzinga
SVB Leerink initiated coverage on OptimizeRx Corporation (NASDAQ: OPRX) with a buy rating and a price target of $38, implying an upside of 36%.
The analysts say OptimizeRx is the largest EHR-embed
SVB Leerink Sees 'Cheaper Way' To Pharma Digital Marketing With This Stock
03:23pm, Friday, 15'th Jul 2022
SVB Leerink initiated coverage on OptimizeRx Corporation (NASDAQ: OPRX) with a buy rating and a price target of $38, implying an upside of 36%. The analysts say OptimizeRx is the largest EHR-embed
Benzinga's Top Ratings Upgrades, Downgrades For July 15, 2022
02:18pm, Friday, 15'th Jul 2022 Benzinga
Upgrades
B of A Securities upgraded the previous rating for TechnipFMC PLC (NYSE:FTI) from Neutral to Buy. For the first quarter, TechnipFMC had an EPS of $0.03, compared to year-ago quarter EPS of $
Where OptimizeRx Stands With Analysts
02:07pm, Friday, 15'th Jul 2022 Benzinga
OptimizeRx (NASDAQ:OPRX) has observed the following analyst ratings within the last quarter:
Bullish
Somewhat Bullish
Indifferent
Somewhat Bearish
Bearish
Total Ratings
1
2
1
0
0
Last 30D
0
OptimizeRx Corp. (OPRX) Moves 8.9% Higher: Will This Strength Last?
02:52pm, Monday, 27'th Jun 2022 Zacks Investment Research
OptimizeRx Corp. (OPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price inc
OptimizeRx: A Small-Cap Digital Health Technology Gem With Near-Term Inflection In Profitability
06:31am, Monday, 27'th Jun 2022
Large and growing TAM with industry tailwinds like digitalization supporting growth in demand for OptimizeRx's solutions. Highly scalable operating model with more than sufficient network capacity to
OptimizeRx Brings Real-World Evidence-Driven Engagement Programs to Social Media With New Exclusive Partnership
11:30am, Thursday, 23'rd Jun 2022 GlobeNewswire Inc.
The latest omni-channel platform extension gives pharma access to up to 84% of prioritized HCPs on social media with content that is specific to their specialty The latest omni-channel platform extens
5 Small-Cap Stocks That Are Diamonds in the Rough
12:27pm, Thursday, 16'th Jun 2022
Small-cap stocks are less liquid, more volatile, and have a lower market cap. But they also offer the opportunity for greater returns.
OptimizeRx’s Mike Rousselle Named One of 2022 PM360 ELITE 100
02:00pm, Tuesday, 17'th May 2022 GlobeNewswire Inc.
ROCHESTER, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on t
OptimizeRx Authorizes $20 Million Share Repurchase Program
12:30pm, Tuesday, 17'th May 2022 GlobeNewswire Inc.
ROCHESTER, Mich., May 17, 2022 (GLOBE NEWSWIRE) -- OptimizeRx Corp. (the “Company”) (Nasdaq: OPRX), a leading provider of point-of-care technology solutions helping patients start and stay on
3 Small-Caps That Might Be Acquisition Candidates
08:00pm, Monday, 09'th May 2022 The Motley Fool
Here's why our roundtable thinks OptimizeRx, Affimed and Blueprint Medicines are all buys right now.
OptimizeRx Corporation (OPRX) CEO William Febbo on Q1 2022 Results - Earnings Call Transcript
10:42pm, Wednesday, 04'th May 2022
OptimizeRx Corporation (NASDAQ:OPRX ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants William Febbo - Chief Executive Officer Ed Stelmakh - Chief Financial Officer & Chief
OptimizeRx Corp. (OPRX) Reports Q1 Loss, Lags Revenue Estimates
09:55pm, Wednesday, 04'th May 2022 Zacks Investment Research
OptimizeRx Corp. (OPRX) delivered earnings and revenue surprises of -200% and 0.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
